Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

As The BioWorld Turns, Part II: Slimming Down With Brownies?

April 9, 2007

By Cynthia Robbins-Roth

As The BioWorld Turns, Part II: Slimming Down With Brownies?

April 9, 2007

By Cynthia Robbins-Roth

As Biotech Turns: Fumbling, Bumbling And Posh Spice

March 26, 2007

By Cynthia Robbins-Roth

As Biotech Turns: Fumbling, Bumbling And Posh Spice

March 26, 2007

By Cynthia Robbins-Roth

Location, Location, Location: Ceregene Bets on Better Delivery

March 12, 2007

By Cynthia Robbins-Roth

Location, Location, Location: Ceregene Bets on Better Delivery

March 12, 2007

By Cynthia Robbins-Roth

Getting Closer to Nature: The BrainCells Way

Feb. 26, 2007

By Cynthia Robbins-Roth

Getting Closer to Nature: The BrainCells Way

Feb. 26, 2007

By Cynthia Robbins-Roth

Is FIPCO Only Way To Go? Try Thinking 'Small Ball'

Feb. 12, 2007

By Cynthia Robbins-Roth

Is FIPCO Only Way To Go? Try Thinking 'Small Ball'

Feb. 12, 2007

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...